Muhanad Hasan, MD
Pulmonary Disease · Tallahassee, FLNPI 1225219058
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 58 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$369
- AstraZeneca$259
- Johnson & Johnson$206
- Intuitive Surgical$118
- Actelion Pharmaceuticals US, Inc.$110
- Watermark Medical, Inc.$90
- plus $532 from 16 others
Across 3 payments — averaging $8467.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$25K
What the payments were for
- Food & beverage$1,685100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 16 | $369 |
| AstraZeneca | 7 | $259 |
| Johnson & Johnson | 2 | $206 |
| Intuitive Surgical | 1 | $118 |
| Actelion Pharmaceuticals US, Inc. | 3 | $110 |
| Watermark Medical, Inc. | 1 | $90 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| Insmed, Inc. | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 5 | $68 |
| Stryker | 1 | $47 |
| Grifols USA, LLC | 2 | $30 |
| Pulmonx Corporation | 1 | $30 |
| Sanofi | 1 | $27 |
| Electromed, Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Resmed Corp | 1 | $19 |
| Fisher & Paykel Healthcare Inc | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$141
- Da Vinci Surgical System$118
- TEZSPIRE$104
How this compares
$1,685 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $103,262 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $21,829 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $14,890 |
| Spiriva HandihalerTiotropium Bromide | 19 | $11,107 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,656 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,385 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,976 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $5,657 |
| Roflumilast | 33 | $5,583 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $4,386 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 102 | $3,141 |
| Armodafinil | 22 | $1,680 |
| Rifampin | 12 | $1,196 |
| Ethambutol Hcl | 12 | $793 |
| Ventolin HfaAlbuterol Sulfate | 13 | $700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $259 | $16,63233 claims |
| Boehringer IngelheimSpiriva Respimat | $369 | $10,38520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Tallahassee
- Carlos CampoTallahassee$87K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.